1. Search Result
Search Result
Results for "

protein kinase inhibitor

" in MedChemExpress (MCE) Product Catalog:

590

Inhibitors & Agonists

10

Screening Libraries

2

Fluorescent Dye

2

Biochemical Assay Reagents

53

Peptides

54

Natural
Products

13

Recombinant Proteins

12

Isotope-Labeled Compounds

8

Antibodies

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-47026

    Checkpoint Kinase (Chk) CDK BMX Kinase Bcr-Abl Aurora Kinase Others
    Protein kinase inhibitor 6 is a protein kinase inhibitor.
    Protein kinase inhibitor 6
  • HY-131900

    PKC Cancer
    Protein kinase inhibitor H-7 is a potent inhibitor of protein kinase C (PKC) and cyclic nucleotide dependent protein kinase, with a Ki of 6 μM for PKC .
    Protein kinase inhibitor H-7
  • HY-401475

    PKC Cardiovascular Disease Inflammation/Immunology Cancer
    Protein kinase inhibitor 9 (Compound example 175) is an inhibitor of serine/threonine and tyrosine kinase activity. Protein kinase inhibitor 9 can be used for the research of cancer, hyper proliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections and imflammatory disorders .
    Protein kinase inhibitor 9
  • HY-100983

    PKC Cancer
    Protein kinase inhibitor H-7 dihydrochloride is a potent PKC (protein kinase C) inhibitor. At 100 μM, Protein kinase inhibitor H-7 dihydrochloride completely inhibits both TPA (skin tumour promoter, 12-O-tetradecanoylphorbol-13-acetate) and phospholipase C-induced ODC (ornithine decarboxylase) .
    Protein kinase inhibitor H-7 dihydrochloride
  • HY-W844543

    Others Neurological Disease
    Protein Kinase Inhibitor 12 (compound 1-93) is a triazolopyridazine derivative and protein kinase inhibitor that can be utilized in research related to diseases associated with protein kinases .
    Protein kinase inhibitor 12
  • HY-155619

    PKC PKA Cancer
    Protein kinase inhibitor 7 is an inhibitor for protein kinase A and protein kinase C. Protein kinase inhibitor 7 affects autocrine motility factor (AMF) signaling pathway, without affecting the cell motility .
    Protein kinase inhibitor 7
  • HY-153745

    Trk Receptor Cancer
    Protein kinase inhibitor 5 is a potent TRK-A inhibitor with an IC50 value of 1.8 nM. Protein kinase inhibitor 5 inhibits cell viability .
    Protein kinase inhibitor 5
  • HY-111093

    CaMK Neurological Disease
    Protein kinase inhibitor 8 (Compound CK59) is a calmodulin-dependent protein kinase II (CaMKII) inhibitor. By inhibiting the activity of CaMKII, Protein kinase inhibitor 8 can attenuate the cytotoxicity induced by perfluorooctane sulfonic acid (PFOS) and alleviate the downregulation of GLT-1 expression caused by PFOS, thereby reducing neuronal damage. Protein kinase inhibitor 8 may be useful in research related to neurodegenerative diseases .
    Protein kinase inhibitor 8
  • HY-153743

    ROS Kinase Trk Receptor Cancer
    Protein kinase inhibitor 4 (Compound 3) is a protein kinase inhibitor that inhibits TRK-A and ROS1 (IC50=3.0 nM and 104 nM respectively) .
    Protein kinase inhibitor 4
  • HY-153745A

    Trk Receptor Cancer
    Protein kinase inhibitor 5 sulfate hydrate is a potent TRK-A inhibitor with an IC50 value of 1.8 nM. Protein kinase inhibitor 5 sulfate hydrate inhibits cell viability .
    Protein kinase inhibitor 5 sulfate hydrate
  • HY-U00439

    DYRK Cancer
    Protein kinase inhibitor 1 is a novel inhibitor of HIPK2 with an IC50 of 74 nM and Kd of 9.5 nM.
    Protein kinase inhibitor 1
  • HY-U00439A
    Protein kinase inhibitor 1 hydrochloride
    3 Publications Verification

    DYRK Cancer
    Protein kinase inhibitor 1 hydrochloride is a potent HIPK2 inhibitor, with IC50s of 136 and 74 nM for HIPK1 and HIPK2, and a Kd of 9.5 nM for HIPK2.
    Protein kinase inhibitor 1 hydrochloride
  • HY-47597

    Bacterial Infection
    Protein kinase G inhibitor-2 (Compound 266) is a mycobacterial protein kinase G inhibitor, with an IC50 of 3 μM. Protein kinase G inhibitor-2 can be used for mycobacterial infection research .
    Protein kinase G inhibitor-2
  • HY-48958

    Bacterial Infection
    Protein kinase G inhibitor-1 (Compound 270) is a mycobacterial protein kinase G inhibitor, with an IC50 of 0.9 μM. Protein kinase G inhibitor-1 can be used for mycobacterial infection research .
    Protein kinase G inhibitor-1
  • HY-151372

    PKD Cancer
    Protein kinase D inhibitor 1 (compound 17m) is a pan-PKD inhibitor, with IC50 values ranging from 17 to 35 nM. Protein kinase D inhibitor 1 inhibits PKD-dependent cortactin phosphorylation .
    Protein kinase D inhibitor 1
  • HY-77048

    IRAK Inflammation/Immunology
    IRAK-4 protein kinase inhibitor 2 (compound 1) is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4), with an IC50 of 4 μM. IRAK-4 protein kinase inhibitor 2 can be used for the research of inflammatory and immune-related conditions or disorders .
    IRAK-4 protein kinase inhibitor 2
  • HY-164041

    PKC Others
    Staurosporine-Boc, a natural product isolated from the actinomyces Streptomyces staurosporeus, is a potent non-selective inhibitor of protein kinase. Staurosporine-Boc inhibits a variety of protein kinases, including protein kinase C (PKC), tyrosine kinase, and serine/threonine kinase. Because of its broad inhibition profile, Staurosporine-Boc is widely used as a tool compound in biological research, especially when studying cell signaling pathways .
    Staurosporine-Boc
  • HY-P5886

    Myristoylated protein kinase C inhibitor 20-28

    PKC Cancer
    PKC 20-28,myristoylated (Myristoylated protein kinase C inhibitor 20-28) is a cell-permeable PKC inhibitor that can be used in cancer research .
    PKC 20-28,myristoylated
  • HY-100984
    HA-100
    1 Publications Verification

    PKA PKC Myosin ROCK Cancer
    HA-100 is a potent protein kinase inhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 also used as a ROCK inhibitor .
    HA-100
  • HY-100984A

    PKA PKC Myosin ROCK Cancer
    HA-100 hydrochloride is a potent protein kinase inhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 hydrochloride also used as a ROCK inhibitor .
    HA-100 hydrochloride
  • HY-12880

    Myosin PKA PKC ROCK Cancer
    HA-100 dihydrochloride is a potent protein kinase inhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 dihydrochloride also used as a ROCK inhibitor .
    HA-100 dihydrochloride
  • HY-P1746
    Protein Kinase C (19-31)
    1 Publications Verification

    PKC (19-31)

    PKC Inflammation/Immunology
    Protein Kinase C (19-31), a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31), is used as protein kinase C substrate peptide for testing the protein kinase C activity .
    Protein Kinase C (19-31)
  • HY-P1288

    PKC fragment (530-558)

    PKC Others
    Protein Kinase C (530-558), a peptide fragment of protein kinase C (PKC), is a potent PKC activator. Protein Kinase C (530-558) significantly inhibits osteoclastic bone resorption .
    Protein Kinase C (530-558)
  • HY-P1746A

    PKC (19-31) (TFA)

    PKC Inflammation/Immunology
    Protein Kinase C (19-31) TFA, a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31), is used as protein kinase C substrate peptide for testing the protein kinase C activity .
    Protein Kinase C (19-31) (TFA)
  • HY-15979
    H-89
    120+ Cited Publications

    PKA Autophagy Neurological Disease
    H-89 is a potent and selective inhibitor of cyclic AMP-dependent protein kinase (protein kinase A) with IC50 of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase, and others kinases.
    H-89
  • HY-112907

    RIP kinase Inflammation/Immunology
    RIP2 Kinase Inhibitor 3 is a highly potent and selective inhibitor of receptor interacting protein-2 (RIP2) Kinase with an IC50 of 1 nM .
    RIP2 Kinase Inhibitor 3
  • HY-10721

    AKT protein kinase inhibitor

    Akt Cancer
    PF-AKT400 is a broadly selective, potent, ATP-competitive Akt inhibitor, displays 900-fold greater selectivity for PKBα (IC50=0.5 nM) than PKA (IC50=450 nM).
    PF-AKT400
  • HY-147612

    c-Met/HGFR Cancer
    Tyrosine kinase-IN-4 (EXAMPLE 107) is a protein tyrosine kinase inhibitor .
    Tyrosine kinase-IN-4
  • HY-101962

    Insulin Receptor Metabolic Disease
    HNMPA is a membrane impermeable insulin receptor tyrosine kinase inhibitor. HNMPA inhibits serine and tyrosine autophosphorylation by the human insulin receptor. HNMPA has no effect on protein kinase C or cyclic AMP-dependent protein kinase activities
    HNMPA
  • HY-117393

    PKC Cancer
    Bisindolylmaleimide III is a potent and selective inhibitor of protein kinase C (PKC). Bisindolylmaleimide III selectively interacts with either PKCα or ribosomal S6 protein kinase 1 after activation of these kinases .
    Bisindolylmaleimide III
  • HY-19761
    RIP2 kinase inhibitor 2
    2 Publications Verification

    RIP kinase Cancer
    RIP2 kinase inhibitor 2 is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043437 A1, compound example 9.
    RIP2 kinase inhibitor 2
  • HY-P1401

    PKC Metabolic Disease
    Protein Kinase C (19-36) is a pseudosubstrate peptide inhibitor of protein kinase C (PKC), with an IC50 of 0.18 μM. Protein Kinase C (19-36) markedly attenuated vascular hyperproliferation and hypertrophy as well as glucose-induced suppression of natriuretic peptide receptor response .
    Protein Kinase C (19-36)
  • HY-18316

    JAK Inflammation/Immunology
    RO495 is a potent inhibitor of non-receptor tyrosine-protein kinase 2 (TYK2 kinase) .
    RO495
  • HY-148297

    LY3871801; R 552

    RIP kinase Inflammation/Immunology
    Ocadusertib is a potent Serine/Threonine kinase receptor-interacting protein kinase 1 (RIPK1) inhibitor .
    Ocadusertib
  • HY-P3892

    PKC Inflammation/Immunology
    Protein Kinase C (19-35) Peptide is the PKC pseudosubstrate inhibitor/region. Protein Kinase C (19-35) Peptide possibly blocks the substrate-binding site in its kinase domain, makes the cytoplasmic form of PKC inactive .
    Protein Kinase C (19-35) Peptide
  • HY-W011109

    Casein Kinase CDK SGK Ribosomal S6 Kinase (RSK) Cancer
    CKI-7 is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 is a selective Cdc7 kinase inhibitor. CKI-7 also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 has a much weaker effect on casein kinase II and other protein kinases .
    CKI-7
  • HY-19805
    STO-609
    15+ Cited Publications

    CaMK AMPK Autophagy Metabolic Disease
    STO-609 is a selective and cell-permeable inhibitor of the Ca 2+/calmodulin-dependent protein kinase kinase (CaM-KK), with Ki values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC50 ~0.02 g/ml.
    STO-609
  • HY-19805A

    CaMK AMPK Autophagy Metabolic Disease
    STO-609 acetate is a selective and cell-permeable inhibitor of the Ca 2+/calmodulin-dependent protein kinase kinase (CaM-KK), with Ki values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 acetate inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC50 ~0.02 g/ml.
    STO-609 acetate
  • HY-10183
    Go6976
    5+ Cited Publications

    PKC Influenza Virus Cancer
    Go6976 is a Protein Kinase C (PKC) inhibitor, with an IC50 of 20 nM.
    Go6976
  • HY-112384

    L-threo-dihydrosphingosine

    PKC Cancer
    Safingol is a lyso-sphingolipid PKC (protein kinase C ) inhibitor .
    Safingol
  • HY-112384A

    L-threo-dihydrosphingosine hydrochloride

    PKC Cancer
    Safingol hydrochloride is a lyso-sphingolipid PKC (protein kinase C ) inhibitor .
    Safingol hydrochloride
  • HY-P3930

    IP20-amide

    PKA Neurological Disease
    PKI (5-24),amide (IP20-amide) is a 20-residue peptide that corresponds to the active portion of the heat-stable inhibitor protein of cAMP-dependent protein kinase. PKI (5-24),amide is a potent cAMP-dependent protein kinase (PKA) (PKA) inhibitor with a Ki of 2.3 nM .
    PKI (5-24),amide
  • HY-13820
    GSK2656157
    45+ Cited Publications

    PERK Autophagy Apoptosis Cancer
    GSK2656157 is a selective and ATP-competitive inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) with an IC50 of 0.9 nM.
    GSK2656157
  • HY-15979A
    H-89 dihydrochloride
    120+ Cited Publications

    PKA Autophagy Others
    H-89 dihydrochloride is a potent and selective inhibitor of protein kinase A (PKA) with an IC50 of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase.
    H-89 dihydrochloride
  • HY-133028
    CKI-7 free base
    1 Publications Verification

    Casein Kinase CDK SGK Ribosomal S6 Kinase (RSK) Cancer
    CKI-7 free base is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 free base is a selective Cdc7 kinase inhibitor. CKI-7 free base also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 free base has a much weaker effect on casein kinase II and other protein kinases .
    CKI-7 free base
  • HY-W013411A

    UIC-1005

    Raf Cancer
    Locostatin (UIC-1005) is a potent RKIP inhibitor. Locostatin binds Raf kinase inhibitor RKIP protein and disrupts the interaction of RKIP with Raf-1 kinase and G protein-coupled receptor kinase 2. Locostatin inhibits cell proliferation and migration. Locostatin can be used to synthesize chemical probes toward PEBP-proteins. Locostatin aggravates thioacetamide (HY-Y0698)-induced acute liver failure in mice .
    Locostatin
  • HY-P0222
    PKI(5-24)
    3 Publications Verification

    PKA Others
    PKI(5-24) is a potent, competitive, and synthetic peptide inhibitor of PKA (cAMP-dependent protein kinase), with a Ki of 2.3 nM. PKI(5-24) corresponds to residues 5-24 in the naturally occurring heat-stable protein kinase inhibitor .
    PKI(5-24)
  • HY-N11003
    Vanicoside A
    1 Publications Verification

    PKC Others
    Vanicoside A is a protein kinase C(PKC) inhibitor from Polygonum pensylvanicum .
    Vanicoside A
  • HY-159846

    MEK Cancer
    Luvometinib is a mitogen-activated protein kinase (MEK) inhibitor with antitumor activity .
    Luvometinib
  • HY-18072
    GSK2606414
    85+ Cited Publications

    PERK Autophagy Apoptosis Cancer
    GSK2606414 is a cell-permeable and orally available protein kinase R-like endoplasmic reticulum (ER) kinase (PERK) inhibitor with an IC50 of 0.4 nM.
    GSK2606414

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: